Overview
AT-R3 (Reta) is a synthetic research peptide classified as a triple hormone receptor agonist, simultaneously targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple receptor mechanism distinguishes AT-R3 from earlier single or dual agonist compounds and has made it a subject of significant interest in metabolic research.
Alpha Tides PNW supplies AT-R3 in multiple vial sizes for laboratory research use. Certificates of Analysis are available for select vial sizes.
Research Applications
- Triple receptor pharmacology: Comparative studies on GLP-1/GIP/glucagon co-activation versus single or dual agonism
- Metabolic research: Body composition and energy expenditure studies in preclinical models
- Hepatic lipid research: Liver lipid content and hepatic steatosis research models
- Cardiovascular research: Metabolic marker modulation and cardiometabolic research
- Energy homeostasis: Glucagon receptor contribution to lipolysis and energy expenditure in combination with incretin signaling
- Insulin secretion studies: GLP-1 and GIP synergism on pancreatic beta-cell response
- Glycemic regulation: Glucose-dependent insulin secretion and gastric emptying modulation
Research Notes
AT-R3 engages three receptor pathways simultaneously. GLP-1 and GIP receptor activation drives increased insulin secretion, improved glucose uptake, increased satiety signaling, and reduced gastric emptying rate in preclinical models. Glucagon receptor co-activation adds a third distinct pathway — increasing energy expenditure, promoting lipolysis, reducing lipogenesis, and contributing additional insulin secretion stimulation. These three pathways act in parallel rather than sequentially — the key mechanistic differentiator separating triple agonists from dual and single agonist compounds.
Ongoing research is examining triple-agonist activity in relation to hepatic lipid content, cardiovascular research markers, and energy homeostasis regulation. As a triple receptor agonist, AT-R3 represents a more complex pharmacological profile than GLP-1 or dual GLP-1/GIP agonists. Researchers should account for the overlapping downstream effects of simultaneous receptor engagement and the potential for additive or synergistic outcomes across metabolic research parameters.
Storage Notes
- Before reconstitution: Store lyophilized vials at −20°C, protected from light and moisture. Allow to reach room temperature before opening.
- After reconstitution: Refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
- Recommended solvent: Bacteriostatic water for most research protocols.
Related Research
- How to Store Research Compounds Properly — Storage protocols for lyophilized compounds
- How to Reconstitute Lyophilized Peptides — Step-by-step reconstitution guide
- Research Hub — Full library of compound guides and research references
AT-R3 (Reta) is intended strictly for laboratory research by qualified professionals. It is not FDA approved and is not for human or animal use. Not intended to diagnose, treat, cure, or prevent any disease. By purchasing, the buyer confirms the product will be used solely for in vitro research in compliance with all applicable laws and regulations.
